Publication Month: Feb 2020 | Report Code: TIPRE00004423 | No. of Pages: 175 | Category: Pharmaceuticals | Status: Published
The superdisintegrants are the agents that are mixed in the tablets to intensify the breakup of the tablet into small fragments in aqueous conditions, thereby boosting the release of the drug into the body. In past years superdisintegrants have gained the attention of the pharmaceutical industry as it increases the solubility of active pharmaceutical ingredient (API) in the body by raising the absorption of the drug in the body due to which bioavailability of drugs also increases. The superdisintegrant agent is used in tablets and capsules. The growth of the Superdisintegrants market is attributed to the growing adoption of orally disintegrating solid dosage forms across the globe and increasing acceptability of generic drugs are expected to boost the market growth over the years. However, high cost associated with the manufacturing of superdisintegrants is likely to have a negative impact on the growth of the market in the coming years.
The Superdisintegrants market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
Get more information on this report :
The world is witnessing exponential growth in the prevalence of chronic diseases. Factors such as progression of viruses, bacteria, parasites, coupled with growing adoption of sedentary lifestyle, genetic conditions, and consumption of poor diet are responsible for the growing prevalence of these diseases. This exponential increase in the prevalence of diseases is leading to the adoption of solid dosage forms for disease treatment. For instance, according to data published by the World Health Organization (WHO) in 2019, an estimated 71.0 million people suffer from hepatitis C virus infection across the world. Oral drug delivery remains the most common route of drug administration in the healthcare world. Solid dosage forms typically includes tablets, capsules, and powders for the treatment of particular disease condition. Moreover, growing emphasis on novel drug delivery approach is expected to boost the awareness and focus on the utilization of orally disintegrating tablets during the forecast period. Superdisintegrants or orally disintegrating tablets are gaining traction due to advantages such as ease of drug administration and better compliance for pediatric and geriatric patients. Furthermore, superdisintegrant tablets offer several benefits over traditional capsules and tablets. Advantages of disintegrants include the ability for accurate dosing, fast action, superior patient compliance, better palatability, and cost effectiveness, as well as ease of administration, no risk of airway suffocation during swallowing, and flexibility in terms of large and small molecules. Such salient features of superdisintegrant tablets represent massive potential for its adoption during tablet formulations. Moreover, on-going research and development activities conducted by major players and research institutes are likely to expand the range of benefits offered by superdisintegrants during the forecast period. Additionally, the increasing adoption of orally disintegrating tablets is attributable to new product launches by several pharmaceuticals companies. For instance, in April 2018, the partnership of Perrigo Company Plc. and Dexcel Pharma Technologies Ltd. launched Omeprazole ODT—orally disintegrating tablets to treat heartburn. The company took strategic step to expand geriatric customer base.
Generic drugs refer to qualitative and quantitative compositions of active components whose bioequivalence has been demonstrated by suitable bioavailability studies. Cost efficiency is the prominent factor that is driving the acceptance and adoption of generic drugs across the world. For instance, according to the study published in Journal of Pharmaceutical Health Care and Sciences (2015), nearly 50.0–60.0% of drug use across the world was of generic drugs. Certain benefits such as superior treatment outcomes, cost benefits, and easy availability played a major part in higher consumption of generic medications. Such higher consumption of generic medications is directly correlated to increased manufacturing of drugs. Moreover, increasing popularity of orally disintegrating drugs is likely to drive the usage of superdisintegrants in generic drugs, which will ultimately drive the growth of the global superdisintegrants market during the forecast period. Additionally, majority of the governments across the world are also implementing strategic policies to encourage the use of generic drugs. For instance, in 2016, the Medical Council of India, recommended physicians to include generic drugs in pharmacy prescriptions to fuel the utilization of generic drugs in the country. As generic drugs are cheaper by about 30.0–80.0%, the government is focusing to increase its adoption with an aim to expand the reach of drugs to every financial class.
In terms of type, the Superdisintegrants market is segmented into synthetic superdisintegrants, natural superdisintegrants, and others. In 2019, the synthetic superdisintegrant segment held the largest share of the market.
Get more information on this report :
Based on formulation, the Superdisintegrants market is segmented into tablets and capsules. In 2019, the tablets segment held the largest share of the market.
In terms of therapeutic area, the Superdisintegrants market is segmented into into neurological diseases, gastrointestinal diseases, oncology, inflammatory diseases, infectious diseases, cardiovascular diseases, and other diseases. In 2019, the gastrointestinal diseases segment held the largest share of the market.
|Market Size Value in||US$ 369.56 Million in 2019|
|Market Size Value by||US$ 659.17 Million by 2027|
|Growth rate||CAGR of 7.6% from 2020-2027|
|No. of Pages||175|
|No. of Tables||119|
|No. of Charts & Figures||72|
|Historical data available||Yes|
|Segments covered||Type ; Formulation ; Therapeutic Area , and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The Superdisintegrants market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.
The List of Companies - Superdisintegrants Market